Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya

E. Wangeci Kagucia,1,6 John N. Gitonga,7 Catherine Kalu,1 Eric Ochomo,2 Benard Ochieng,2 Nickline Kuya,2 Angelza Karon,1 James Nyangwange,1 Boniface Kari,1 Daisy Muga,1 Henry K. Karanja,1 James Tuju,1 Agnes Mutiso,1 Hosea Maroko,9 Lucy Okabi,2 Eric Maitha,2 Hassan Ajuck,2 David Mukabi,5 Wycliffe Moracha,2 David Bulimu,5 Nelson Andanje,5 Rashid Aman,6 Mercy Mwangangi,6 Patrick Amoth,6 Kedoni Kasera,4 Wangari Ng‘ang’a,7 Ameek Nyaguara,1 Shirine Voller,1 Mark Otieno,3 Christian Bottenley,9 Charles N. Agoti,2 Lynette I. Ochola-Oyier,1 Hedyo M. O. Adetila,1 Anthony O. Etyang,1 Katherine E. Gallagher,1 Sophie Uyoga,1 Edwine Barasa,1 Philip Bejon,1 Benjamin Tsiofa,1 Ambrose Agwoya,1 George M. Warimwe,1,9 and J. Anthony G. Scott1,8,9,a

1KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya, 2KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya, 3KEMRI Centre for Infectious and Parasitic Diseases Control Research, Busia, Kenya, 4Department of Health, Kilifi County, Kenya, 5Department of Health, Busia County, Kenya, 6Ministry of Health, Government of Kenya, Nairobi, Kenya, 7Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya, 8Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 9Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom

In October 2020, anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G seroprevalence among truck drivers and their assistants (TDA) in Kenya was 42.3%, higher than among healthcare workers and blood donors. Truck drivers and their assistants transport essential supplies during the coronavirus disease 2019 pandemic, placing them at increased risk of being infected and of transmitting SARS-CoV-2 over a wide geographical area.

Keywords. antibody seroprevalence; frontline workers; Kenya; SARS-CoV-2; truck drivers.

Serosurveillance for antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to estimate the cumulative incidence of SARS-CoV-2 infection. This is of particular interest among frontline workers, such as truck drivers, who are exempted from coronavirus disease 2019 (COVID-19) restrictions such as curfews and lockdowns.

Shortly after the first locally detected SARS-CoV-2 infection in March 2020, the Government of Kenya instituted containment measures, including travel restrictions. Freight transportation was excluded from travel restrictions because truckers and drivers’ assistants (TDA) were deemed essential workers [1]. In May 2020, the Kenya Ministry of Health implemented mandatory bimonthly SARS-CoV-2 nucleic acid testing (NAT) for long-distance TDA, in line with East African Community guidelines [2, 3]. Although NAT data can be used to estimate the cumulative incidence of SARS-CoV-2 infection [4], accurate estimates are dependent on the availability of reliable model parameter values.

There are currently no estimates of SARS-CoV-2 antibody seroprevalence among TDA globally. Due to the nature of their work, TDA interact with a wide variety of social and professional contacts over a large geographical area, putting them at increased risk of SARS-CoV-2 infection. We undertook a serosurvey to estimate the prevalence of SARS-CoV-2 antibodies among TDA in Kenya.

METHODS

Study Design and Participants

A cross-sectional serosurvey was conducted at 3 sites: 1 in Kilifi County in South-Eastern Kenya and 2 in Busia County in Western Kenya (Supplementary Figure 1). In Kilifi County, TDA transporting salt domestically and to East African countries (eg, Uganda, Rwanda and Burundi) were engaged at salt harvesting companies located in Gongoni area, Magarini Sub-County. In Busia County, TDA were engaged at One Stop Border Posts (OSBPs) in 2 border towns, Busia and Malaba. Truckers and drivers’ assistants at Busia OSBP and Malaba OSBP typically transport freight between Mombasa, Kenya and countries in East Africa (Supplementary Figure 2).

Truckers and drivers’ assistants were eligible if they were aged ≥18 years without a medical contraindication for blood sample collection. Participation was voluntary and verbal consent was sought before blood sample collection. Serosurveillance was conducted as a public health activity requested by the Kenya Ministry of Health, and ethical approval for publication of these data was obtained from the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085).

Patient Consent Statement

The study did not include factors necessitating patient consent.

Data and Sample Collection

Sociodemographic and clinical data, including age, sex, nationality, residence, temperature, and symptoms of illness within the previous 2 weeks, were collected by county public health
staff (CPHS) and recorded on governmental COVID-19 surveillance forms (Supplementary Forms 1 and 2). Venous blood samples were collected using standard blood sample collection procedures and labeled with the same unique identifier as nasopharyngeal/oropharyngeal (NP/OP) samples. The NP/OP NAT results, linked using the unique identifiers, were obtained from testing laboratories. Data with personal identifiers were retained only by CPHS.

**Laboratory Testing**

Plasma was extracted from blood samples using standard techniques and stored at −80°C before antibody testing. Thawed plasma samples were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) using a locally validated whole spike enzyme-linked immunosorbent assay (ELISA) with 93% sensitivity and 99% specificity, as described previously [5, 6]. Spike ELISA positivity was defined as a ratio of sample optical density (OD) over negative control OD >2. The NP/OP NAT results are routinely provided to TDA by CPHS. Serology results were also provided to TDA by CPHS.

**Statistical Analysis**

At least 700 samples were required to estimate seroprevalence as low as 2% within a 1% margin of error. Age was categorized into 10-year strata. Crude seroprevalence was estimated as the number of anti-SARS-CoV-2 IgG-positive samples (OD ratio >2) divided by all samples, and associated exact binomial 95% confidence intervals (CIs) were calculated. Bayesian adjustment for assay sensitivity and specificity was performed as previously described [6]. Associations between seropositivity and sociodemographic/clinical characteristics were tested using χ² or Fisher’s exact tests. Test-performance-adjusted seroprevalence and credible intervals were calculated in R (version 3.6.1) with RStan. All other analyses were performed using Stata (version 15.1).

**RESULTS**

The serosurvey was conducted in Magarini between September 30 and October 23, 2020 and in Busia County on October 13–15, 2020. In total, 830 TDA (Busia OSBP n = 365; Magarini n = 101; Malaba OSBP n = 364) provided a blood sample, representing 52.4% of TDA approached (Supplementary Figure 3). Of the 830 samples, 91.1% were collected between October 13 and 15, 2020 (Supplementary Figure 4). The median age of sampled TDA was 40 years (interquartile range, 34–48 years) and 668 (80.5%) were Kenyan. Only 3 (0.4%) of the TDA were female (Table 1). Among Kenyan TDA, reported county of residence included 31 of the country’s 47 counties. The most common counties of residence were Mombasa, Uasin Gishu, and Nakuru (Supplementary Table 1). Driver versus assistant role was not recorded, but, on the basis of truck driver licensure age requirements, at least 53 (6.6%) were assistants (Table 1).

Of 785 TDA with available NAT results, 58 (7.4%) were positive for SARS-CoV-2 (Table 1); positivity was significantly higher among younger TDA (Table 1). The crude anti-SARS-CoV-2 IgG prevalence was 39.6% (95% CI 36.3–43.1) and test-performance adjusted prevalence was 42.3% (95% CI 38.4–46.3) (Table 1).

**Table 1. Crude and Test-Performance Adjusted Anti-SARS-CoV-2 IgG Seroprevalence Among TDA in Kenya, September 30 to October 23, 2020**

| Characteristic | N     | Seropositive | %:Crude anti-SARS-CoV-2 IgG Seroprevalence | 95% Confidence Interval | %:Adjusted Anti-SARS-CoV-2 IgG Seroprevalence | 95% Credible Interval |
|---------------|-------|--------------|-------------------------------------------|-------------------------|-----------------------------------------------|-----------------------|
| Total         | 830   | 329          | 39.6                                      | 36.3–43.1               | 42.3                                          | 38.4–46.3             |
| Agea          |       |              |                                           |                         |                                               |                       |
| <30 years     | 92    | 42           | 45.7                                      | 35.2–56.4               | 49.1                                          | 38.1–59.9             |
| 30–39 years   | 276   | 110          | 39.9                                      | 34.0–45.9               | 42.4                                          | 35.5–49.1             |
| 40–49 years   | 286   | 116          | 40.6                                      | 34.8–46.5               | 43.4                                          | 37.4–49.9             |
| 50–59 years   | 135   | 48           | 35.6                                      | 27.5–44.2               | 38.1                                          | 29.2–47.4             |
| >60 years     | 38    | 13           | 34.2                                      | 19.6–51.4               | 37.0                                          | 22.3–54.1             |
| Sex           |       |              |                                           |                         |                                               |                       |
| Male          | 827   | 326          | 39.4                                      | 36.1–42.8               | 42.1                                          | 38.1–46.7             |
| Female        | 3     | 3            | 100.0                                     | 29.2–100.0              | 79.6                                          | 379–99.3              |
| NAT Resulta   |       |              |                                           |                         |                                               |                       |
| Positive      | 58    | 32           | 55.2                                      | 41.5–68.3               | 59.0                                          | 46.0–72.1             |
| Negative      | 727   | 270          | 37.1                                      | 33.6–40.8               | 39.6                                          | 35.0–43.9             |
| Nationality   |       |              |                                           |                         |                                               |                       |
| Kenya         | 668   | 262          | 39.2                                      | 35.5–43.0               | 41.9                                          | 37.7–46.0             |
| Other         | 162   | 67           | 41.4                                      | 33.7–49.4               | 44.2                                          | 36.3–52.5             |
| Site          |       |              |                                           |                         |                                               |                       |
| Busia OSBP    | 365   | 163          | 44.7                                      | 39.5–49.9               | 47.9                                          | 42.3–53.8             |
| Magarini      | 101   | 43           | 42.6                                      | 32.8–52.8               | 45.2                                          | 35.1–55.9             |
| Malaba OSBP   | 364   | 123          | 33.8                                      | 28.9–38.9               | 36.0                                          | 30.8–41.9             |

Abbreviations: IgG, immunoglobulin G; NAT, nucleic acid test; OSBP, One Stop Border Post; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TDA, truck drivers and assistants. 

aMissingness: age, n = 3; NAT result, n = 45.
higher in Magarini (25 of 93; 26.9%) compared to Busia OSBP (15 of 348; 4.3%) and Malaba OSBP (18 of 344; 5.2%; P < .001) (Supplementary Table 2). None of the 830 TDA reported current or previous symptoms of illness. Only 1 individual had a temperature of 37.5°C or higher (Supplementary Table 2) and the NAT result was negative in that 1 case.

Crude overall anti-SARS-CoV-2 IgG seroprevalence among sampled TDA was 39.6% (95% CI, 36.3–43.1). After adjustment for assay sensitivity and specificity it was 42.3% (95% credible interval [CrI], 38.4–46.3). Seroprevalence was highest in TDA <30 years of age and lowest among those aged ≥50 years. All 3 female TDA were seropositive for anti-SARS-CoV-2 IgG. Seroprevalence was 39.6% (95% CrI, 35.0–43.9) among TDA negative for SARS-CoV-2 by NAT and 59.0% (95% CrI, 46.0–72.1) among those with a positive SARS-CoV-2 NAT result. Seroprevalence among Kenyan TDA was comparable to that of other nationalities. By site, seroprevalence was highest at Busia OSBP and lowest at Malaba OSBP. Crude heterogeneity tests and uncertainty intervals for antibody test-adjusted estimates suggested no significant association between seroprevalence and age and significant differences in seroprevalence by site (Table 1 and Supplementary Table 3).

**DISCUSSION**

We estimate that approximately 4 in 10 TDA in Kenya had been infected with SARS-CoV-2 by late October 2020, as the country experienced the initial stages of a second pandemic wave (Supplementary Figure 5). This study is notable for being the first to report SARS-CoV-2 seroprevalence among TDA.

Anti-SARS-CoV-2 IgG seroprevalence among TDA was more than 4-fold higher compared to average seroprevalence among Kenyan blood donors by September 2020 [7] and 2-fold higher compared to average seroprevalence in healthcare workers (HCWs) across 5 Kenyan health facilities by October 2020 [8]. As such, the findings suggest that the cumulative incidence of SARS-CoV-2 among TDA in Kenya was higher than in the general population and in other frontline workers.

Outside Kenya, some studies found 44%–45% seroprevalence of SARS-CoV-2 antibodies among HCWs, comparable to that among TDA in Kenya [9–11]. However, meta-analyses of studies globally estimated SARS-CoV-2 antibody prevalence among HCWs at 7% by July 2020 [12] and 9% by August 2020 [13]. Taken together, these data suggest that exposure to SARS-CoV-2 among TDA was higher than among HCWs in most settings.

To date, few studies have assessed SARS-CoV-2 antibody prevalence in nonhealthcare frontline workers. Seroprevalence was 38% seroprevalence among male migrant supermarket workers in Kuwait in May to June 2020 [14]. Elsewhere, however, seroprevalence among non-HCWs has been lower, ranging from 1% [15] to 22% [16].

None of the NAT-positive TDA reported symptoms within 2 weeks of testing, suggesting predominantly asymptomatic COVID-19 among TDA. Although data on symptoms may have been subject to reporting bias, 93% of SARS-CoV-2 infections confirmed in Kenya by October 23, 2020 were asymptomatic [17]. The similarity in anti-SARS-CoV-2 antibody seropositivity among Kenyan and non-Kenyan TDA indicates predominantly occupation-related exposure to SARS-CoV-2. The fact that seroprevalence differed by sampling site suggests some heterogeneity in exposure risk.

Despite sampling at 3 different sites, we cannot be sure that the sample included are representative of all TDA in Kenya, or even those transiting through these sites. Participation in the serosurvey was voluntary, only half of those approached agreed to be sampled, and sociodemographic data for the target population are not available. However, data on county of residence for Kenyan TDA indicates representation from most counties. Seroprevalence estimates did not account for clustering by site or by driver-assistant pairs. The use of antibodies to estimate cumulative incidence of SARS-CoV-2 infection assumes universal seroconversion, minimal mortality, and antibody persistence. If these assumptions are incorrect—for example, there is evidence suggestive of antibody waning [18–20]—the cumulative incidence of infection would be underestimated. To minimize bias due to assay sensitivity and specificity, adjusted seroprevalence estimates were calculated.

**CONCLUSIONS**

These findings indicate substantial cumulative incidence of SARS-CoV-2 infection—most of which was asymptomatic—among TDA in Kenya, despite prevention measures. The occupational nature of haulage entails interaction with many contacts over large geographical areas; as such, TDA may unintentionally contribute to the spread of emerging infections. These findings illustrate the challenge of infection prevention within an occupational group whose role in sustaining supply chains remains vital during a pandemic. In addition, they underscore the importance of national and regional preparedness plans for the safe continuation of haulage in future pandemics.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

We thank the truck drivers and assistants for their participation. We thank the Busia Transporters Chairman for support in engaging truck drivers and assistants. We thank the Busia and Kilifi County Health Management Teams (CHMTs), Busia Port Health, Malaba Port Health, and Gongoni area salt companies for their support of this activity, including training support by Busia and Kilifi CHMT members. We thank the Director, KEMRI Centre.
for Global Health Research and Director, KEMRI Centre for Infectious and Parasitic Diseases Control Research for collaborative agreements to support field and laboratory work. We are grateful to A. Okemwa and E. Murunga (KEMRI-CIPDCRB) for supporting sample processing of samples collected in Busia. We thank the following KEMRI-Wellcome Trust Research Programme teams: the COVID-19 Laboratory Team; the Pneumococcal Conjugate Vaccine Impact Study (PCVIS) team for supporting sample collection training, field supervision and data entry; the COVID-19 data team; and the Community Engagement team (Supplementary Table 4). We thank F. Krammer (Icahn School of Medicine at Mount Sinai, New York, USA) for providing the plasmids used to generate the spike protein used in this work. Members of the Magarini Sub-County TDA SARS-CoV-2 Serosurveillance Team and the Busia County TDA SARS-CoV-2 Serosurveillance Team are listed in the Supplement. This paper has been published with the permission of the Director, Kenya Medical Research Institute.

Author contributions. E. W. K., J. N. G., C. K., E. O., B. O., N. K., B. K., D. M., H. K. K., J. T., E. M., H. A., D. M., W. M., D. B., N. A., R. A., M. M., P. A., K. K., W. N., A. N., S. V., L. I., O. O., I. M. O. A., I. M. O. A., A. O. E., K. E. G., S. U., E. B., P. B., T. A. A., A. M. W., and J. A. G. S. contributed to conceptualization and design; C. K., B. O., N. K., L. O., and L. I. O.-O. contributed to data acquisition; J. N. G., A. K., J. N., D. M., H. K. K., J. T., A. M., H. M., L. O., C. A. N., K. I.-O., and G. M. W. contributed to laboratory methodologies and analysis; E. W. K., C. K., B. K., M. O., and C. B. contributed to data analysis; E. W. K., C. B., I. M. O. A., A. O. E., K. E. G., S. U., E. B., P. B., T. A. A., G. M. W., and J. A. G. S. contributed to data interpretation; E. W. K., A. K., A. M. W., and J. A. G. S. contributed to data preparation; J. N. G., C. K., E. O., B. O., N. K., A. K., J. N., B. K., D. M., H. K. K., J. T., A. M., H. M., L. O., E. M., H. A., D. M., W. M., D. B., N. A., R. A., M. M., P. A., K. K., W. N., A. N., S. V., M. O., C. B., C. N. A., L. I. O.-O., I. M. O. A., A. O. E., K. E. G., S. U., E. B., P. B., T. A. A., G. M. W., and J. A. G. S. contributed to reviewing and editing.

Disclaimer. For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies.

Financial support. This project was funded by the Wellcome Trust (Grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill & Melinda Gates Foundation (INV-017547), and the Foreign, Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated program of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. Development of SARS-CoV-2 reagents was partially supported by the National Institute of Allergy and Infectious Diseases (NIAID) Centres of Excellence for Influenza Research and Surveillance (CEIRS) (contract HHSN272201400008C). A. A. is funded by a Department for International Development (DFID)/Medical Research Council (MRC)/National Institutes of Health Research (NIHR)/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1). J. A. G. S. is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIH Health Protection Research Unit in Immunisation. I. M. O. A. is funded by the United Kingdom’s MRC and DFID through an African Research Leader Fellowship (MR/S005293/1) and by the NIH-Mucosal Pathogens Research Unit (MPRU) at UCL (Grant 2268427 LSHTM). G. M. W. is supported by a fellowship from the Oak Foundation. C. N. A. is funded by the Developing Excellence in Leadership, Training and Science (DELTAS) Africa Initiative (DEL-15-003), and the Foreign, Commonwealth and Development Office and Wellcome (220985/Z/20/Z). S. U. is funded by DELTAS Africa Initiative (DEL-15-003). L. I. O.-O. is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z).

Potential conflicts of interest. R. A. M., M. K., and P. A. are from the Ministry of Health, Government of Kenya. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. EAC Secretariat. EAC administrative guidelines to facilitate movement of good and services during the COVID-19 pandemic 2020. Available at: http://repository.eac.int/handle/11671/2058. Accessed 21 December 2020.
2. Ministry of Health Government of Kenya. Update of coronavirus in the country and response measures, as at 7th May, 2020. Available at: https://www.health.go.ke/wp-content/uploads/2020/05/CamScanner-05-07-2020-16.32.06.pdf. Accessed 21 December 2020.
3. Ministry of Health Government of Kenya. Protocol for control of COVID-19 at ground crossings and along the transport corridors. Available at: https://admin.kemri-kenya.att.org/media/Truckers%20Protocol.pdf. Accessed 21 January 2021.
4. Reese H, Iuliano AD, Patel NN, et al. Estimated incidence of COVID-19 illness and hospitalization—United States, February-September, 2020. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1780.
5. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020; 26:1033–6.
6. Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 2021; 371:79–82.
7. Adetifa IMO, Uyoga S, Gitonga JN, et al. Temporal trends of SARS-CoV-2 seroconversion during the first wave of the COVID-19 epidemic in Kenya. Nat Commun 2021; 12:3966.
8. Etyang AO, Lucinde R, Karanja H, et al. Seroprevalence of antibodies to SARS-CoV-2 among health care workers in Kenya. Clin Infect Dis 2021. doi: 10.1093/cid/ciaa346.
9. Houlihan CF, Vora N, Byrne T, et al.; Crick COVID-19 Consortium; SAFER Investigators. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. Lancet 2020; 396:e6–7.
10. Hains DS, Schwander AE, Carroll AE, et al. Asymptomatic seroconversion of immunoglobulins to SARS-CoV-2 in a pediatric dialysis unit. JAMA 2020; 323:2424–5.
11. Olayanju O, Bamidele O, Edem F, et al. SARS-CoV-2 seroconversion in asymptomatic frontline health workers in Ibadan, Nigeria. Am J Trop Med Hyg 2020. doi: 10.4269/ajtmh.20-1235.
12. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in health-care workers: a living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol 2021; 190:161–75.
13. Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect 2021; 108:120–34.
14. Alâli WQ, Bastaki H, Longenecker JC, et al. Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait. J Travel Med 2020. doi: 10.1136/jtm.2020.002223.
15. Jerković I, Ljubić Ţ, Basic Ţ, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Šibenik-Knin County, Croatia. J Occup Environ Med 2020. doi: 10.1097/JOM.0000000000002020.
16. Poustchi H, Darvishian M, Mohammadi Z, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis 2021; 21:473–81.
17. Ministry of Health Government of Kenya. COVID-19 outbreak in Kenya: Daily Situation Report. Nairobi: Ministry of Health Government of Kenya; 2020. 16 p. Report No: 220.
18. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200–4.
19. Ibarondon FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383:1085–7.
20. Self WH, Tenforde MW, Stubblefield WB, et al.; CDC COVID-19 Response Team; IVY Network. Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multisite hospital network—12 states, April-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1762–6.